When 10 pallets change a 10,000-pallet warehouse

He adds: “You can suddenly find yourself redesigning large parts of a facility because of requirements tied to a few pallets.”

That fact is becoming increasingly important for both pharmaceutical companies and third-party logistics providers, also known as 3PLs. As supply chains become more specialized, warehouse design decisions are increasingly influenced by the most demanding materials rather than the largest product volumes.

Consider a warehouse designed to store 10,000 pallets of standard pharmaceutical products. The project may appear relatively straightforward from a fire safety, ventilation, and insurance perspective.

Then a client introduces a small quantity of flammable material. And suddenly, the discussion changes.

Fire compartments may need redesign. Ventilation systems may require upgrades. ATX zoning may become relevant. Emergency response requirements may change. Insurance acceptance may need reassessment. In some cases, authority dialogue can become significantly more complex.

One of the clearest lessons emerging in pharma logistics is that the stored material itself determines the design requirements. Hazardous and flammable materials introduce entirely different design considerations compared to standard pharma products. The questions quickly become more complicated.

How much material will be stored? In what format? What is the flash point? Does the material create explosion risk? Can it be segregated? How will it affect fire strategy, ventilation, drainage, emergency access, or insurance approval?

In some cases, projects must also comply with ATEX requirements. ATEX is the European regulatory framework covering environments where explosive atmospheres may occur due to flammable gases, vapours, or dust.

Morgan explains: “The challenge is that several approval worlds suddenly need to align at the same time. The fire department, insurers, pharma QA teams, local authorities, EHS specialists, and operators may all look at the same facility from completely different perspectives.”

And those perspectives do not always point toward the same solution. A technically acceptable pharma solution may not satisfy fire safety requirements. A commercially attractive layout may create insurance challenges. A warehouse optimised for operational efficiency may become problematic from an emergency-response perspective.

The challenge is not simply technical compliance. The challenge is understanding whether the most demanding products should define the entire facility.

In some cases, designing around a small hazardous-material inventory can introduce costs and complexity that far outweigh the operational value.

“You have 10 pallets in a 10,000-pallet warehouse that suddenly introduce requirements making the whole facility significantly more expensive or operationally complicated,” says Morgan.

That creates a difficult but important question. Should the entire facility be designed around the most demanding exception? Increasingly, the answer is no. Instead, project teams are evaluating whether certain hazardous or flammable products should be handled separately in specialist facilities rather than allowing a small exception to dictate the design of the entire warehouse.

The question is no longer whether the material can be stored. The question is whether it should be stored inside the same facility. That distinction can have major implications for investment costs, approval timelines, operational complexity, and long-term profitability.

Why early decisions matter most

This is why early scoping is becoming one of the most important advisory disciplines in modern pharma logistics. The earlier project teams understand the implications of hazardous materials, flammable products, storage conditions, and operational requirements, the greater the opportunity to avoid expensive redesigns later.

Early engineering involvement can help identify challenges before they become embedded in the project.

Morgan says: “All these disciplines influence each other. That is why early engineering involvement creates so much value. You are not just designing a warehouse. You are shaping the long-term operational and commercial viability of the facility.”

For pharmaceutical companies, that means lower risk, smoother approvals, and facilities that better support future growth. For 3PL providers, it means creating logistics assets that are safe, approvable, insurable, operationally practical, and commercially realistic.

The pharmaceutical logistics market continues to grow rapidly, driven by biologics, GLP-1 therapies, vaccines, and increasingly specialised products requiring highly controlled storage environments.

But many of the most important warehouse decisions are no longer driven by the largest product categories. They are driven by the exceptions.

A handful of pallets containing hazardous or flammable materials can influence fire strategy, insurance acceptance, operational procedures, authority approvals, and investment costs across an entire facility.

That is why successful projects increasingly begin with a simple question:

Which products should define the warehouse, and which products should not? Because in modern pharmaceutical logistics, the biggest challenge is not always the 10,000 pallets.